Atai Beckley N.V. is a clinical-stage biopharmaceutical company focused on developing treatments for difficult-to-treat mental health disorders, with a portfolio centered on psychedelic and related novel compounds. The company was formed in 2025 through the strategic combination of atai Life Sciences and Beckley Psytech, bringing together multiple late-stage and earlier-stage programs under one platform. Its business model is still pre-commercial, so value creation depends on advancing product candidates through clinical development, securing regulatory approvals, and eventually commercializing or partnering the assets. In parallel, the company also operates a drug-delivery and research-services business through Nualtis, which provides development services and manufacturing capabilities around oral thin-film technology.
−33 187,7 %
−48 464,0 %
−1,9 %
3.21
3.21
| % | |
|---|---|
| Clinical-stage product candidates | 0% Investigational mental-health therapies in preclinical and clinical development, including psychedelic compounds and related novel chemical entities. |
| Research and development services | 100% Fee-based R&D work performed for customers using Nualtis's oral thin-film drug delivery platform. |
| License and collaboration revenue | 0% Milestone, royalty, and other collaboration-based revenue tied to partnered programs and technology licensing. |
| Drug delivery technology and manufacturing | 0% Oral thin-film formulation know-how and manufacturing capabilities that can support both internal candidates and third-party programs. |
The company’s core customers are not traditional commercial drug buyers; instead, its primary economic counterparties...
Companies that license technology, fund development, or share in milestones and royalties for pipeline assets and delivery platforms.
Customers that pay Nualtis to perform research and development work using its oral thin-film technology and may later become manufacturing clients.
Patients with treatment-resistant depression, alcohol use disorder, major depressive disorder, and other hard-to-treat mental health conditions targeted by the pipeline.
Capital providers and biotech partners that support clinical advancement, portfolio expansion, and transaction activity such as the Beckley Psytech combination.
Atai Beckley is headquartered in the United States, but its operating footprint is international and includes research,...
The company’s strategy is to concentrate resources on clinical-phase programs and near-term data catalysts that can...
Clinical data is the main value driver in a pre-commercial biotech model and determines whether assets can be partnered, approved, or commercialized.
The transaction expands the company’s portfolio and should improve scale, diversification, and the number of upcoming clinical catalysts.
Partnerships can reduce funding burden, validate assets, and create non-dilutive economics before full commercialization.
The drug-delivery business can generate service revenue and support manufacturing rights tied to future approved products.
The company faces the core biotech risk that its product candidates may never advance successfully through clinical...
The company’s core assets are investigational and may not demonstrate sufficient efficacy, safety, or tolerability in trials.
Even successful trial data may not translate into approval, especially for novel psychedelic-based therapies.
Current revenue depends on a small number of collaboration and R&D service arrangements and can fluctuate sharply by period.
The Beckley Psytech combination must close and then be integrated operationally and scientifically to realize expected value.
The company is not yet commercially self-funding and may need additional capital to support development and operations.
The company operates across jurisdictions, creating translation and transaction exposure.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
BTAI · Pharmaceutical Preparations
NEUP · Pharmaceutical Preparations
BIVI · Pharmaceutical Preparations
ADIL · Pharmaceutical Preparations
ALMS · Pharmaceutical Preparations
: 11/08/2026